Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

Yuan Wang,Zhe Wang,Jiacheng Liu,Yunwen Wang,Rui Wu,Rong Sheng,Tingjun Hou

DOI: https://doi.org/10.1016/j.bmc.2021.116096

2021-04-01

Abstract:HBV capsid assembly has been regarded as an attractive potential target for anti-HBV therapy. In this study, we discovery the Novel HBV capsid assembly modulators (CAMs) through structure-based virtual screening and bioassays. A total of 16 structurally diverse compounds were purchased and assayed, including three compounds with inhibition rate > 50% at 20 μM. Further lead optimization based on the most potent compound II-1-7 (EC50 = 5.6 ± 0.1 µM) were performed by using substructure searching strategy, resulting in compound II-2-9 with an EC50 value of 1.8 ± 0.6 μM. In bimolecular fluorescence complementation (BiFC) assay, compound II-2-9 inhibited the HBV by disrupting the HBV capsid interactions. In summary, this study provides a highly efficient way to discover novel CAMs, and 2-aryl-4-quinolyl amide derivatives could serve as the starting point for development of novel anti-HBV drugs.

biochemistry & molecular biology,chemistry, medicinal, organic

What problem does this paper attempt to address?

This paper aims to address the issue of Hepatitis B virus (HBV) infection, particularly focusing on the critical step of HBV capsid assembly. Currently, the main drugs for treating HBV infection include nucleoside analogs and interferons, but these drugs have problems such as side effects or drug resistance. Therefore, it is especially important to develop new anti-HBV drugs with different mechanisms of action. The paper, through structure-based virtual screening and bioassay methods, discovered a series of novel HBV capsid assembly modulators (CAMs). Specifically, the researchers used the crystal structure of the known HBV core protein with the modulator complex for virtual screening, selecting 16 structurally diverse compounds for testing, among which three compounds showed more than 50% inhibition at a concentration of 20 μM. Further lead optimization based on the most effective compound II-1–7 (EC50 = 5.6 ± 0.1 µM) through a substructure search strategy ultimately yielded compound II-2–9, with an EC50 value of 1.8 ± 0.6 μM. Additionally, the study validated the effect of compound II-2–9 in inhibiting HBV by disrupting HBV capsid interactions through bimolecular fluorescence complementation (BiFC) experiments. Overall, this research provides an efficient method for discovering new CAMs, and 2-aryl-4-quinolinecarboxamide derivatives can serve as a starting point for developing new anti-HBV drugs.

Discovery of novel HBV capsid assembly modulators by structure-based virtual screening and bioassays

The SAR-based Development of Small Molecular HBV Capsid Assembly Modulators

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Pharmacophore-Based Virtual Screening and Structural Modification of Novel Benzamide Derivatives as HBV Capsid Assembly Modulators

Design, synthesis and anti-HBV activity study of novel HBV capsid assembly modulators

Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay

Development of Benzimidazole-Based Compounds As Novel Capsid Assembly Modulators for the Treatment of HBV Infection

Discovery Of (1h-Pyrazolo[3,4-C]Pyridin-5-Yl)Sulfonamide Analogues As Hepatitis B Virus Capsid Assembly Modulators By Conformation Constraint

Design, synthesis and biological evaluation of novel dihydrobenzodioxine derivatives as HBV capsid protein inhibitors

Structure-Based Discovery of <i>N</i>-Sulfonylpiperidine-3-Carboxamides as Novel Capsid Assembly Modulators for Potent Inhibition of HBV Replication

Synthesis and evaluation of N-sulfonylpiperidine-3-carboxamide derivatives as capsid assembly modulators inhibiting HBV in vitro and in HBV-transgenic mice

Discovery of novel small molecules targeting hepatitis B virus core protein from marine natural products with HiBiT-based high-throughput screening

Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies

An automated microfluidic platform for the screening and characterization of novel hepatitis B virus capsid assembly modulators

Small Molecule Assembly Agonist Alters the Dynamics of Hepatitis B Virus Core Protein Dimer and Capsid

The premise of capsid assembly modulators towards eliminating HBV persistence

A prodrug of the capsid assembly modulator improved druggability and lowing HBsAg and HBeAg for the treatment of chronic hepatitis B

Rational Design, Synthesis, and Structure-Activity Relationship of a Novel Isoquinolinone-Based Series of HBV Capsid Assembly Modulators Leading to the Identification of Clinical Candidate AB-836

Discovery of Novel Hepatitis C Virus NS5B Polymerase Inhibitors by Combining Random Forest, Multiple e-Pharmacophore Modeling and Docking

Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1h)-one Derivatives As Anti-Hbv Agents Targeting at Capsid Assembly